Clinical Trial Search

Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 1 — 8.3; 13.8; 21.9; 27.0 micrograms*hour/milliliter (mcg*h/mL)

Primary: The Incidence of Major Cardiovascular and/or Renal Adverse Events Related to the Renal Denervation Procedure That Occurred Within 30 Days Post-procedure. — 0.0…

Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 2920; 2860; 2710 nmol*h/L

Primary: Cmax - Maximum Observed Plasma Concentration — 327.8; 750.1 ng/mL

Primary: Cmax - Maximum Observed Plasma Concentration of 9-1067 — 600; 567; 955; 917 ng/mL

Primary: Cumulative Recovery of [14C]-Radioactivity — 12.8; 67.2; 15.9; 95.9 Recovery % of dose

Primary: Cmax - Maximum Observed Plasma Drug Concentration — 647; 703; 640; NA ng/mL

Primary: Cmax - Maximum Observed Plasma Concentration — 400; NA; 11.6; 9.76 ng/mL

Primary: Number of Participants With Clinically Significant Clinical Laboratory Results — 3; 0; 1; 1 participants

Primary: Cmax - Maximum Observed Plasma Concentration — NA; 672; 643; 6152 ng/mL

Primary: Cmax - Maximum Plasma Concentration of Levodopa — 1076; 1106; 943; 981 ng/mL

Primary: Best Objective Response Based on RECIST Criteria (Evaluable for Response Analysis Set for RECIST Criteria) — 0; 0; 0; 0 Participants

Primary: Cmax - Maximum Observed Plasma Concentration of Levodopa — 896; 1088; 1014; 889 ng/mL

Primary: Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration — -6.7; -7.0…

Primary: Pharmacodynamic (PD) Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post…